Recessive mutations in the NBEAL2 gene lead to grey platelet syndrome (GPS), characterized by macrothrombocytopenia, α-granule-deficient platelets, bleeding disorders, and (in some cases) splenomegaly and progression to myelofibrosis1–3. Here, NBEAL2 is linked to hemorrhagic disease.